-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Cero Therapeutics Holdings, Inc. annual/quarterly Income Tax Expense (Benefit) history and growth rate from Q3 2021 to Q3 2023.
- Cero Therapeutics Holdings, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2023 was $25.8K, a 57.4% decline year-over-year.
- Cero Therapeutics Holdings, Inc. annual Income Tax Expense (Benefit) for 2023 was $94.8K, a 84.2% decline from 2022.
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)